Woodline Partners LP Invests $6.09 Million in Atyr PHARMA INC (NASDAQ:ATYR)

Woodline Partners LP purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,683,000 shares of the company’s stock, valued at approximately $6,092,000. Woodline Partners LP owned 2.01% of Atyr PHARMA as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of ATYR. JPMorgan Chase & Co. lifted its holdings in shares of Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after purchasing an additional 10,754 shares during the period. Kingswood Wealth Advisors LLC acquired a new position in Atyr PHARMA in the fourth quarter valued at $170,000. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA in the fourth quarter valued at $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA in the fourth quarter valued at $141,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Atyr PHARMA in the fourth quarter valued at $144,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ATYR shares. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Monday, May 19th. Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price on the stock. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Price Performance

Shares of NASDAQ ATYR opened at $3.75 on Friday. The firm’s 50-day moving average price is $3.24 and its 200-day moving average price is $3.42. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66. The firm has a market capitalization of $333.77 million, a P/E ratio of -3.99 and a beta of 0.79. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. Equities research analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.